Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;20(11):709-713.
doi: 10.1038/s41577-020-00460-4. Epub 2020 Oct 6.

Cross-reactive memory T cells and herd immunity to SARS-CoV-2

Marc Lipsitch  1 , Yonatan H Grad  2 , Alessandro Sette  3   4 , Shane Crotty  5   6
Affiliations
Review

Cross-reactive memory T cells and herd immunity to SARS-CoV-2

Marc Lipsitch et al. Nat Rev Immunol. 2020 Nov.

Abstract

Immunity is a multifaceted phenomenon. For T cell-mediated memory responses to SARS-CoV-2, it is relevant to consider their impact both on COVID-19 disease severity and on viral spread in a population. Here, we reflect on the immunological and epidemiological aspects and implications of pre-existing cross-reactive immune memory to SARS-CoV-2, which largely originates from previous exposure to circulating common cold coronaviruses. We propose four immunological scenarios for the impact of cross-reactive CD4+ memory T cells on COVID-19 severity and viral transmission. For each scenario, we discuss its implications for the dynamics of herd immunity and on projections of the global impact of SARS-CoV-2 on the human population, and assess its plausibility. In sum, we argue that key potential impacts of cross-reactive T cell memory are already incorporated into epidemiological models based on data of transmission dynamics, particularly with regard to their implications for herd immunity. The implications of immunological processes on other aspects of SARS-CoV-2 epidemiology are worthy of future study.

PubMed Disclaimer

Conflict of interest statement

A.S. is a consultant for Gritstone, Flow Pharma, Merck and Avalia. S.C. is a consultant for Avalia and JPMorgan. M.L. discloses honoraria/consulting from Merck, Affinivax, Sanofi-Pasteur and Antigen Discovery; research funding (institutional) from Pfizer; and unpaid scientific advice to Janssen, AstraZeneca, 1DaySooner and Covaxx (United Biomedical). Y.H.G. discloses consulting from Merck and Quidel; and research funding (institutional) from Pfizer.

Figures

Fig. 1
Fig. 1. Schematic models of the three major scenarios wherein cross-reactive CD4+ memory T cells have a positive impact on control of SARS-CoV-2 replication in an individual and reduce COVID-19 disease severity.
Timelines of viral burden in the lungs and upper respiratory tract (URT) and of immune responses, which differ according to the magnitude and type of pre-existing cross-reactive CD4+ T cell memory. Model 1 makes no specific prediction about antibody response kinetics or magnitude, because it could be mediated by different types of immune response with equivalent disease outcomes (see main text). Under scenario 4, there would be no infection in individuals with cross-reactive immunity (scenario therefore not shown). Each of these models is currently hypothetical for SARS-CoV-2. TFH cell, T follicular helper cell; TRM, tissue-resident memory cell.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sette A, Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat. Rev. Immunol. 2020;20:457–458. doi: 10.1038/s41577-020-0389-z. - DOI - PMC - PubMed
    1. Doshi P. Covid-19: do many people have pre-existing immunity? BMJ. 2020;370:m3563. doi: 10.1136/bmj.m3563. - DOI - PubMed
    1. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368:860–868. doi: 10.1126/science.abb5793. - DOI - PMC - PubMed
    1. Grifoni A, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–1501.e15. doi: 10.1016/j.cell.2020.05.015. - DOI - PMC - PubMed
    1. Braun J, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020 doi: 10.1038/s41586-020-2598-9. - DOI - PubMed

Publication types

MeSH terms